Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.36 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.35 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.35 |
| ▸ | HPGDS | O60760 | 4/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL313808 | 0.74 | MASP2 (0.44) | NPY5RHPGDS | |
| SCHEMBL28175769 | 0.74 | GSK3B (0.36) | MAPK8GSK3BNPY5RHPGDS | |
| SCHEMBL5887078 | 0.72 | NPC1 (0.41) | CYP2A6NPY5RHPGDSNPC1PKM | |
| SCHEMBL1441687 | 0.72 | ALDH1A1 (0.37) | NPY5RHPGDS | |
| SCHEMBL27647142 | 0.69 | HPGDS (0.33) | NPY5RHPGDS | |
| SCHEMBL5820674 | 0.69 | HPGDS (0.33) | NPY5RHPGDS | |
| SCHEMBL5309026 | 0.69 | NPY5R (0.39) | NPY5RHPGDS | |
| SCHEMBL15880173 | 0.69 | HPGDS (0.33) | NPY5RHPGDS | |
| SCHEMBL30083304 | 0.69 | PIN1 (0.37) | GSK3BNPY5RHPGDS | |
| SCHEMBL27443658 | 0.69 | GSK3B (0.41) | MAPK8GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0662834-A4 | NOVEL EPOXIDE-CONTAINING COMPOUNDS. | CELL THERAPEUTICS INC (US) | 1996-04-17 | — | — | EP | claimed |
| EP-0662834-A1 | NOVEL EPOXIDE-CONTAINING COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1995-07-19 | — | — | EP | claimed |
| WO-1994006431-A1 | NOVEL EPOXIDE-CONTAINING COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1994-03-31 | — | — | WO | claimed |
| EP-3943490-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | Mission Therapeutics Limited (GB) | 2022-01-26 | — | — | EP | disclosed |
| US-11066365-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2021-07-20 | — | — | US | disclosed |
| EP-3277677-B9 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2021-07-14 | — | — | EP | disclosed |
| US-11053198-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2021-07-06 | — | — | US | disclosed |
| EP-3842427-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | Mission Therapeutics Limited (GB) | 2021-06-30 | — | — | EP | disclosed |
| EP-3277677-B1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2021-02-24 | — | — | EP | disclosed |
| US-10689345-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2020-06-23 | — | — | US | disclosed |
| US-20200181086-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2020-06-11 | — | — | US | disclosed |
| US-20190322624-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2019-10-24 | — | — | US | disclosed |
| US-20190284138-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2019-09-19 | — | — | US | disclosed |
| US-20190270708-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2019-09-05 | — | — | US | disclosed |
| US-10343992-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | Missions Therapeutics Limited (GB) | 2019-07-09 | — | — | US | disclosed |
| US-20180086708-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2018-03-29 | — | — | US | disclosed |
| WO-2016156816-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2016-10-06 | — | — | WO | disclosed |
| EP-0662834-A4 | NOVEL EPOXIDE-CONTAINING COMPOUNDS. | CELL THERAPEUTICS INC (US) | 1996-04-17 | — | — | EP | disclosed |
| EP-0662834-A1 | NOVEL EPOXIDE-CONTAINING COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1995-07-19 | — | — | EP | disclosed |
| WO-1994006431-A1 | NOVEL EPOXIDE-CONTAINING COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1994-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066365-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | USP30, USP20, USP10 | CYP2A6 3378/4885MAPK8 4390/4885GSK3B 2646/4885 |
| US-10343992-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | USP30, USP20, USP10 | CYP2A6 3808/4885MAPK8 3537/4885GSK3B 2610/4885 |
| US-11053198-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | USP30, USP20, USP10 | CYP2A6 3808/4885MAPK8 3537/4885GSK3B 2610/4885 |
| US-20200181086-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | USP30, USP20, USP10 | CYP2A6 3794/4885MAPK8 3484/4885GSK3B 2512/4885 |
| US-20190284138-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | USP30, USP20, USP10 | CYP2A6 3378/4885MAPK8 4390/4885GSK3B 2646/4885 |
| US-20180086708-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | USP30, USP20, USP10 | CYP2A6 3808/4885MAPK8 3537/4885GSK3B 2610/4885 |
| US-20190322624-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | USP30, USP20, USP10 | CYP2A6 3808/4885MAPK8 3537/4885GSK3B 2610/4885 |
| US-10689345-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | USP30, USP20, USP10 | CYP2A6 3808/4885MAPK8 3537/4885GSK3B 2610/4885 |
| US-20190270708-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | USP30, USP20, USP10 | CYP2A6 3808/4885MAPK8 3537/4885GSK3B 2610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.